The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Dr. Fang Xie, Of Counsel, Greenberg Traurig, LLP will speak at the Knowledge Congress' webcast entitled: "Patent Protection for Pharma and Biotechnology in 2016 LIVE Webcast."  This event is scheduled for Monday, April 18, 2016 @ 3:00 PM to 5:00 PM (ET).

For further details, please visit:

About Dr. Fang Xie

Fang Xie, Ph.D., is of counsel in Greenberg Traurig, LLP's Boson office where she focuses her practice on developing, evaluating, and enforcing intellectual property rights. She has broad experience in worldwide patent and trademark portfolio development, intellectual property due diligence, licensing and technology transfer, patentability and product clearance studies, patent infringement and validity analyses, freedom to operate evaluations, as well as intellectual property litigation and pre-litigation counseling. Dr. Xie's primary technical areas include biotechnology, synthetic biology, and pharmaceuticals, with a focus on nucleic acid synthesis, protein and organism engineering, antibody and biologics/biosimilars, stem cell technology, regenerative medicine, biomarkers, genetic diagnostics, small molecule drugs, analytical chemistry, and cosmetics. She regularly works with clients in the life sciences sector, including biotechnology, pharmaceutical, and chemistry companies, as well as venture capital and institutional investors.

About Greenberg Traurig, LLP

Greenberg Traurig, LLP is an international, multi-practice law firm with approximately 1,900 attorneys serving clients from 38 offices in the United States, Latin America, Europe, Asia, and the Middle East. The firm is No. 1 on the 2015Law360 Most Charitable Firms list, third largest in the U.S. on the 2015 Law360 400, Top 20 on the 2015 Am Law Global 100, and among the 2015 BTI Brand Elite.

Event Synopsis:

The biotechnology industry is a dynamic sector that creates stable jobs and opens opportunities for economic growth in many different countries, particularly in America. Without a robust and strongly enforceable patent protection, investment in biotech innovation may decrease.

Ironically, though, in 2015, the biotech sector has seen an erosion of patent rights due to Supreme Court decisions. Despite this and other threats to both biotech and pharmaceutical patents, companies are turning for help in dealing with the increasing number of patent validity challenges and post-grant review proceedings.

In this overly-competitive patent landscape, protecting pharmaceutical and biotechnology innovation demands for effective strategies.

In this two-hour LIVE Webcast, The Knowledge Group has assembled a panel of key thought leaders that will help pharma and biotech companies understand the critical issues on Patent Protection for Pharma and Biotechnology. They will also offer best strategies and practices with regards to this significant topic.

In this LIVE Webcast, the speakers will discuss:

• Notable Supreme Court Decisions Affecting Pharma and Biotech Industry

• Mayo Collaborative Servs. v. Prometheus Labs., Inc.
• Molecular Pathology v. Myriad Genetics
• Limelight Networks, Inc v. Akamai Technologies, Inc.

• Patent Protection Challenges Post Mayo, Myriad and Limelight
• Best Strategies on Protecting Patent for Pharma and Biotech Innovation
• Up-to-date Legislative Trends on Pharma and Biotech Patents

About The Knowledge Group/The Knowledge Congress Live Webcast Series

The Knowledge Congress was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: